Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology

Summary

Analysis of the individual radiosensitivity in pediatric oncology

Eligibility

Inclusion Criteria:

* Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes.
* Children or adolescents \> 3 years old and \< 18 years old
* Patient with an indication for radiotherapy as part of the primary tumor local control strategy
* Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used
* Patient affiliated with a social security scheme
* Patient and/or parents or holders of parental authority having dated and signed an informed consent

Exclusion criteria:

* Patients with contraindications to blood sampling
* Patients with contraindications to radiotherapy
* Palliative radiotherapy
* Patient with previous RT treatment in the same area (re-irradiation)
* Patient with an indication of hypofractionated RT
* Patient follow-up not possible
* Persons deprived of liberty or under guardianship (including curatorship)

Exclusion Criteria:

\-

Conditions4

Interventions1

Related trials

• Angiogenic Biomarkers in Juvenile Idiopathic Arthritis — Assistance Publique - Hôpitaux de Paris
• Basal Plasma Lithium Levels and Suicidal Events — University Hospital, Montpellier
• Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects — Institut National de la Santé Et de la Recherche Médicale, France
• Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia — Centre Hospitalier Universitaire, Amiens
• Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas — Assistance Publique Hopitaux De Marseille
• Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial — Centre Hospitalier Universitaire, Amiens
• Creation of a French South-Eastern Database and DNA-bank of Congenital Heart Disease to Explore the Genetic Pathways — Assistance Publique Hopitaux De Marseille
• Detection of ISUP≥2 Prostate Cancers Using Multiparametric MRI: Prospective Multicenter Comparison of the PI-RADS Score and an Artificial Intelligence System — Hospices Civils de Lyon

Browse More Trials